Toxoplasma Patents (Class 424/273.1)
  • Patent number: 8962265
    Abstract: Cloning and characterization of a TgIF2? kinase from Toxoplasma gondii designated TgIF2K-D illustrates that this protein is related to GCN2, an eIF2? kinase known to respond to nutrient starvation in other organisms. TgIF2K-D is present in the cytosol of both intra- and extracellular Toxoplasma and facilitates translational control through TgIF2? phosphorylation in extracellular parasites. Both a TgIF2K-D knockout parasite and a parasite harboring the TgIF2? mutant (S71A substitution) exhibited loss of eIF2? kinase activity which manifested itself as significant fitness defect. Accordingly, eIF2? phosphorylation and translational control are an important mechanism by which vulnerable extracellular parasites protect themselves which searching for a new host cell. TgIF2K-D is an excellent target for development of compounds and therapies that can be used to treat infections caused by Toxoplasma and other eukaryotic parasites, especially parasites that have high homology or identity to TgIF2K-D.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: February 24, 2015
    Assignee: Indiana University Research and Technology Corp.
    Inventors: William J. Sullivan, Jr., Ronald C. Wek
  • Publication number: 20140377307
    Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.
    Type: Application
    Filed: October 8, 2013
    Publication date: December 25, 2014
    Applicant: GEORGIA REGENTS RESEARCH INSTITUTE, INC.
    Inventors: DAVID MUNN, ANDREW MELLOR
  • Patent number: 8709445
    Abstract: This invention provides compositions for inducing an immune response in a vertebrate host against a protozoan parasite. In certain embodiments the composition comprises a protozoan parasite comprising a psoralen-modified DNA, whereby said protozoan parasite is killed but metabolically active (KBMA); and optionally a Toll-like receptor agonist.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: April 29, 2014
    Assignee: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Noah A. Craft, Kevin W. Bruhn, Ron A. Birnbaum
  • Publication number: 20140037716
    Abstract: The present invention relates to immunogenic compositions for modulating the immune system, comprising a therapeutically effective quantity of two or more immuno-active antigenic agents with pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs) and one or more physiologically acceptable carriers, excipients, diluents or solvents. The immunogenic compositions according to the present invention are used for producing medicaments for preventing and/or treating, and for preventing and/or treating infectious diseases, auto-immune diseases, allergic diseases, inflammation, arthritis, inflammatory diseases, transplant rejection, affections caused by vascular disorders, diseases caused by haemorrhagic or ischaemic cardiovascular accidents, ischaemia, heart attack and haemorrhagia leading to tissue destruction, heart, kidney, respiratory or liver insufficiency, cancer, malign and benign tumours and neoplasia.
    Type: Application
    Filed: March 19, 2012
    Publication date: February 6, 2014
    Inventor: Alexandre Eduardo Nowill
  • Publication number: 20130142829
    Abstract: Cloning and characterization of a TgIF2? kinase from Toxoplasma gondii designated TgIF2K-D illustrates that this protein is related to GCN2, an eIF2? kinase known to respond to nutrient starvation in other organisms. TgIF2K-D is present in the cytosol of both intra- and extracellular Toxoplasma and facilitates translational control through TgIF2? phosphorylation in extracellular parasites. Both a TgIF2K-D knockout parasite and a parasite harboring the TgIF2? mutant (S71A substitution) exhibited loss of eIF2? kinase activity which manifested itself as significant fitness defect. Accordingly, eIF2? phosphorylation and translational control are an important mechanism by which vulnerable extracellular parasites protect themselves which searching for a new host cell. TgIF2K-D is an excellent target for development of compounds and therapies that can be used to treat infections caused by Toxoplasma and other eukaryotic parasites, especially parasites that have high homology or identity to TgIF2K-D.
    Type: Application
    Filed: June 6, 2011
    Publication date: June 6, 2013
    Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: William J. Sullivan, JR., Ronald C. Wek
  • Publication number: 20120308598
    Abstract: The present invention relates to peptides comprising at least one antigenic determinant or epitope of an apicomplexan Ferlin, Ferlin-like protein and/or another C2-domain containing protein for use as malaria vaccines. It further relates to compositions comprising said peptides and to the use of such compositions as malaria vaccines.
    Type: Application
    Filed: December 6, 2010
    Publication date: December 6, 2012
    Inventors: Ann-Kristin Mueller, Eva Morath
  • Publication number: 20120308604
    Abstract: A vaccine adjuvant which, based on the 100% mass thereof, includes between 10% and 95% of a mineral oil containing: between 0.05 mass-% and 10 mass-% hydrocarbon chains having less than 16 carbon atoms, and between 0.05 mass-% and 5 mass-% hydrocarbon chains having more than 28 carbon atoms. In addition, the adjuvant has a P/N ratio, corresponding to the ratio of the mass quantity of the paraffinic hydrocarbon chains to the mass quantity of the naphthenic hydrocarbon chains, of between 2.5 and 3, the adjuvant being intended for the production of a vaccine composition to prevent coccidiosis.
    Type: Application
    Filed: January 14, 2011
    Publication date: December 6, 2012
    Applicant: SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC
    Inventors: Laurent Dupuis, Francois Bertrand, Sebastien Deville
  • Patent number: 8293224
    Abstract: Uracil auxotroph mutants of apicomplexans are provided which lack a functional carbamoyl phosphate synthase II (CPSII) enzyme. Also provided are T. gondii autoxtroph mutants which express exogenous antigens, and methods of protecting an animal against a T. gondii and non-T. gondii disease.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: October 23, 2012
    Assignee: Trustees of Dartmouth College
    Inventors: David Bzik, Barbara Fox
  • Patent number: 8282942
    Abstract: The present invention provides attenuated Toxoplasma gondii knockout mutants of the de novo pyrimidine synthesis pathway and use of the same in vaccines and methods of providing an immune response and protecting a subject against infection by T. gondii and a non-T. gondii disease.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: October 9, 2012
    Assignee: Trustees of Dartmouth College
    Inventors: David J. Bzik, Barbara A. Fox
  • Publication number: 20120237544
    Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.
    Type: Application
    Filed: September 21, 2010
    Publication date: September 20, 2012
    Applicant: Royal Holloway and Bedford New College
    Inventors: Simon Michael Cutting, Hong Anh Huynh
  • Publication number: 20120177677
    Abstract: Provided are peptide vaccines including the signal peptide domain of selected target antigens of intracellular pathogens. The peptide vaccines of the invention contain multiple class II and class I-restricted epitopes and are recognized and presented by the majority of the vaccinated human population. Further provided, in particular, are anti tuberculosis vaccines. Also further provided are compositions including the vaccines as well as their use to treat or prevent infection.
    Type: Application
    Filed: July 15, 2010
    Publication date: July 12, 2012
    Applicant: VAXIL BIOTHERAPEUTICS LTD.
    Inventor: Lior Carmon
  • Patent number: 8216593
    Abstract: The present invention includes compositions and methods for the development and use of a vaccine that includes one or more FusM antigens in a carrier adapted to trigger a FusM-specific immune response in the human blood stream.
    Type: Grant
    Filed: September 15, 2007
    Date of Patent: July 10, 2012
    Assignees: Board of Regents, The University of Texas System, Imperial College of London
    Inventors: William J. Snell, Yanjie Liu, Robert E. Sinden, Oliver Billker, Rita Tewari
  • Publication number: 20120045477
    Abstract: The present invention provides attenuated Toxoplasma gondii mutants for use as vaccines in the prevention or treatment of cancer.
    Type: Application
    Filed: October 19, 2011
    Publication date: February 23, 2012
    Applicant: Trustees of Dartmouth College
    Inventors: David J. Bzik, Barbara A. Fox, Steven N. Fiering, Jose R. Conejo-Garcia, Jason Baird
  • Patent number: 8058249
    Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: November 15, 2011
    Assignees: University of Iowa Research Foundation, United States of America as represented by the Department of Health and Human Services, Coley Pharmaceutical Group, Inc.
    Inventors: Arthur M. Krieg, Joel Kline, Dennis Klinman, Alfred D. Steinberg
  • Publication number: 20110182847
    Abstract: Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxicity) that may otherwise result in some patients of the TNF-R agonist is used as a monotherapy (without the type 1 interferon and/r TLR agonist).
    Type: Application
    Filed: June 16, 2008
    Publication date: July 28, 2011
    Inventors: Randolph Noelle, Ross Kedl, Cory Ahonen
  • Patent number: 7968096
    Abstract: This invention relates to a method for treatment of latent Toxoplasma gondii infection. The invention provides for the use of Hsp90 inhibitors for treatment of latent Toxoplasma gondii infection, particularly in an immunocompromised subject. Also provided is a screening method for identifying compounds useful for treating latent Toxoplasma gondii infection.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: June 28, 2011
    Assignee: The University of Vermont and State Agricultural College
    Inventors: Mariana L. Matrajt, Sergio O. Angel, Pablo C. Echeverria
  • Patent number: 7964185
    Abstract: The invention relates to attenuate mutated strains of apicomplex of a family of Sarcocystidae, containing inactivated MIC1 and MIC3 adhesins and to the use thereof for a vaccine.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: June 21, 2011
    Assignees: Institut National de la Recherche Agronomique, Centre National de la Recherche Scientifique, Universite Francois Rabelais
    Inventors: Jean-François Dubremetz, Daniel Bout, Maryse Lebrun, Martine Soête, Odile Cerede
  • Publication number: 20110111015
    Abstract: Vaccines comprising TRAP polypeptides and Salmonella enteritidis vectors comprising TRAP polypeptides are provided. The vaccines may also include a CD 154 polypeptide capable of binding to CD4Q. Also provided are methods of enhancing an immune response against Apicomplexan parasites and methods of reducing morbidity associated with infection with Apicomplexan parasites.
    Type: Application
    Filed: November 3, 2008
    Publication date: May 12, 2011
    Inventors: Walter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Mandy Cox, Sherryll Layton, Said El-Ashram, John Barta, Guillermo Tellez
  • Publication number: 20110091526
    Abstract: Compositions and methods for the development and use of a vaccine that includes one or more FusM antigens in a carrier adapted to trigger a FusM-specific immune response in the human blood stream are disclosed herein.
    Type: Application
    Filed: October 6, 2010
    Publication date: April 21, 2011
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, IMPERIAL COLLEGE OF LONDON
    Inventors: William J. Snell, Yanjie Liu, Oliver Billker, Robert E. Sinden, Rita Tewari
  • Patent number: 7867503
    Abstract: A method for treatment or prevention of Toxoplasma gondii infections pharmaceutical composition comprising an antigen fragments of Toxoplasma gondii in the form of a chimeric fusion product or a nucleotide sequence coding for the chimeric fusion product and a method of using the chimeric fusion product or nucleotide sequence coding therefor.
    Type: Grant
    Filed: September 6, 2007
    Date of Patent: January 11, 2011
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Nicola Gargano, Elisa Beghetto, Andrea Spadoni
  • Publication number: 20100310606
    Abstract: This invention provides compositions for inducing an immune response in a vertebrate host against a protozoan parasite. In certain embodiments the composition comprises a protozoan parasite comprising a psoralen-modified DNA, whereby said protozoan parasite is killed but metabolically active (KBMA); and optionally a Toll-like receptor agonist.
    Type: Application
    Filed: July 31, 2008
    Publication date: December 9, 2010
    Applicant: LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER
    Inventors: Noah A. Craft, Kevin W. Bruhn, Ron A. Birnbaum
  • Publication number: 20100284963
    Abstract: Immunogenic compositions comprising growth regulatable recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but are not limited to, growth regulatable and growth limited recombinant intracellular pathogen immunogenic compositions.
    Type: Application
    Filed: April 10, 2007
    Publication date: November 11, 2010
    Inventors: Marcus A. Horwitz, Michael V. Tullius
  • Publication number: 20100260804
    Abstract: Uracil auxotroph mutants of apicomplexans are provided which lack a functional carbamoyl phosphate synthase II (CPSII) enzyme. Also provided are T. gondii autoxtroph mutants which express exogenous antigens, and methods of protecting an animal against a T. gondii and non-T. gondii disease.
    Type: Application
    Filed: December 17, 2008
    Publication date: October 14, 2010
    Inventors: David J. Bzik, Barabara A. Fox
  • Publication number: 20100247537
    Abstract: Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (?-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.
    Type: Application
    Filed: April 25, 2008
    Publication date: September 30, 2010
    Inventors: Cory Ahonen, Randolph Noelle
  • Patent number: 7803389
    Abstract: The present invention relates to a mutant Toxoplasma gondii which exhibits enhanced homologous recombination. The mutant of the present invention is a knockout in the KU80-dependent nonhomologous end-joining pathway which finds application in generating T. gondii gene knockouts and gene replacements for use in vaccine and drug development.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: September 28, 2010
    Assignee: Trustees of Dartmouth College
    Inventors: David J. Bzik, Barbara A. Fox
  • Patent number: 7790187
    Abstract: The invention described herein relates to a method for combining antigen fragments of Toxoplasma gondii proteins, in the form of chimeric fusion products, and their use as diagnostic and immunogenic agents.
    Type: Grant
    Filed: February 27, 2006
    Date of Patent: September 7, 2010
    Assignee: Kenton S.R.L.
    Inventors: Nicola Gargano, Elisa Beghetto, Andrea Spadoni
  • Publication number: 20100203085
    Abstract: The present invention provides attenuated Toxoplasma gondii knockout mutants of the de novo pyrimidine synthesis pathway and use of the same in vaccines and methods of providing an immune response and protecting a subject against infection by T. gondii and a non-T. gondii disease.
    Type: Application
    Filed: April 6, 2010
    Publication date: August 12, 2010
    Inventors: David J. Bzik, Barbara A. Fox
  • Publication number: 20100183547
    Abstract: Recombinant immunogenic compositions, and methods for the manufacture and use, are provided for the prevention and treatment of intracellular pathogen diseases in humans and animals. The recombinant immunogenic compositions express high levels of recombinant proteins in vectors that do not harbor an antibiotic resistance marker (“unmarked”).
    Type: Application
    Filed: June 12, 2008
    Publication date: July 22, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Marcus A. Horwitz, Michael V. Tullius
  • Publication number: 20100040615
    Abstract: The invention relates to a digalactolipidic antigen exposed on the surface of apicomplex parasites, in the form of a vegetable-type digalactoglycerolipid, and adapted for inducing the production of specific antibodies capable of inhibiting the proliferation and/or the invasive properties of said parasites; the invention also relates to a derived antibody or functional antibody fragment, and to their diagnostic, immunotherapeutic and vaccine applications in human beings or animals.
    Type: Application
    Filed: February 7, 2008
    Publication date: February 18, 2010
    Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE, CENTRE NATIONAL DE LA RECHERCHE SEIENTIFIQUE
    Inventors: Cyrille Botte, Nadia Saidani, Maryse Block, Jean-Francois Dubremetz, Henri Vial, Marie-France Cesbron-Delauw, Corinne Mercier, Eric Marechal
  • Publication number: 20090181056
    Abstract: The present invention relates to a mutant Toxoplasma gondii which exhibits enhanced homologous recombination. The mutant of the present invention is a knockout in the KU80-dependent nonhomologous end-joining pathway which finds application in generating T. gondii gene knockouts and gene replacements for use in vaccine and drug development.
    Type: Application
    Filed: February 27, 2009
    Publication date: July 16, 2009
    Inventors: David J. Bzik, Barbara A. Fox
  • Patent number: 7550150
    Abstract: The present invention relates to methods of treating or preventing a disease, disorder or condition associated with a viral infection using a dosing and resting regimen for administering a pharmaceutical composition that provides ARP.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: June 23, 2009
    Assignee: Barros Research Institute
    Inventors: Barnett Rosenberg, John W. Judge
  • Publication number: 20090092630
    Abstract: A method for treatment or prevention of Toxoplasma gondii infections pharmaceutical composition comprising an antigen fragments of Toxoplasma gondii in the form of a chimeric fusion product or a nucleotide sequence coding for the chimeric fusion product and a method of using the chimeric fusion product or nucleotide sequence coding therefor.
    Type: Application
    Filed: September 6, 2007
    Publication date: April 9, 2009
    Inventors: Nicola Gargano, Elisa Beghetto, Andrea Spadoni
  • Patent number: 7510715
    Abstract: The instant invention relates to methods for treating a subject suffering from or susceptible to an autoimmune disease or disorder, or a disease or disorder having an autoimmune component, comprising administering to the subject an effective amount of cyclophilin or a biologically active fragment thereof.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: March 31, 2009
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Julio Aliberti, John Andersen, Hana Golding, Alan Sher
  • Publication number: 20090053266
    Abstract: The invention relates to attenuate mutated strains of apicomplex of a family of Sarcocystidae, containing inactivated MIC1 and MIC3 adhesins and to the use thereof for a vaccine.
    Type: Application
    Filed: January 13, 2005
    Publication date: February 26, 2009
    Inventors: Jean-Francois Dubremetz, Daniel Bout, Maryse Lebrun, Martine Soete, Odile Cerede
  • Publication number: 20080311156
    Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.
    Type: Application
    Filed: July 11, 2008
    Publication date: December 18, 2008
    Inventors: Martin FRIEDE, Nathalie Garcon, Catherine Marie Ghislaine Gerard, Philippe Hermand
  • Publication number: 20080241075
    Abstract: The present invention includes compositions and methods for the development and use of a vaccine that includes one or more FusM antigens in a carrier adapted to trigger a FusM-specific immune response in the human blood stream.
    Type: Application
    Filed: September 15, 2007
    Publication date: October 2, 2008
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, IMPERIAL COLLEGE OF LONDON
    Inventors: William Snell, Yanjie Liu, Robert Sinden, Oliver Billker
  • Publication number: 20080124363
    Abstract: Uracil auxotroph mutants of apicomplexans are provided which lack a functional carbamoyl phosphate synthase II (CPSII) enzyme. Also provided are T. gondii autoxtroph mutants which express exogenous antigens, and methods of protecting an animal against a T. gondii and non-T. gondii disease.
    Type: Application
    Filed: December 21, 2007
    Publication date: May 29, 2008
    Inventors: David Bzik, Barbara Fox
  • Patent number: 7276232
    Abstract: The present invention relates to compositions containing different stages of pathogenic protozoans in a gel and to their use for controlling rodents.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: October 2, 2007
    Assignee: Bayer CropScience AG
    Inventors: Jochen Kalbe, Thomas Böcker, Stefan Endepols, Thomas Jäkel, Sermasakdi Hongnark
  • Patent number: 7067315
    Abstract: The present invention provides novel assay systems and methods for monitoring cell invasion by protozoal parasites. The present invention further provides methods of using these assays systems to identify compounds that treat or prevent protozoal infection. The present invention further provides pharmaceutical compositions that have anit-protozoal activity and methods of treating infections.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: June 27, 2006
    Assignees: President and Fellows of Harvard College, University of Vermont
    Inventors: Nicholas J. Westwood, Gary E. Ward, Kimberly L. Carey, Timothy J. Mitchinson
  • Patent number: 7029678
    Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses.
    Type: Grant
    Filed: September 3, 2003
    Date of Patent: April 18, 2006
    Assignee: SmithKline Beecham Biologicals (S.A.)
    Inventors: Patricia Marie Momin, Nathalie Marie-Josephe Garcon
  • Patent number: 6998126
    Abstract: A method for obtaining an immunogenic strain useful for producing a vaccine against Coccidiosis comprises the cycle of infecting at least one first group of specific pathogen-free donor birds with oocysts from an Eimeria species. Blood is then collected from these donor birds, and is then used to infect a second group of specific pathogen-free birds. Oocysts are collected from the second group of birds. These oocysts are then multiplicated to complete the cycle. The cycle is then repeated using the multiplicated oocysts. After a total of about three cycles, a final antigen may be harvested and utilized as a source to generate oocysts for a vaccine.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: February 14, 2006
    Assignee: Wyeth
    Inventor: Frans Gerrit Davelaar
  • Patent number: 6902926
    Abstract: The invention provides polypeptide fragments derived from TgAMA-1, nucleic acids that encode the polypeptide fragments, and TgAMA-binding polypeptides such as antibodies. Methods for using the polypeptide and nucleic acid molecules to produce vaccines are also provided. In addition the invention provides methods involving use of the polypeptides, nucleic acids, and binding polypeptides, such as antibodies, for the prevention and treatment of Toxoplasmosis.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: June 7, 2005
    Assignees: University of Vermont and State Agricultural College, McGill University
    Inventors: Gary E. Ward, Carolyn G. Conant, Brian Ward
  • Patent number: 6780415
    Abstract: An animal model for CNS infection by Apicomplexan parasites was produced by inoculating a homologous cell or other type of cell with the merozoite stage of the Apicomplexan parasite and inoculating the infected homologous cell or a cell line prepared therefrom back into the host from which it came. Such a model was used to develop drugs for treatment or prophylaxis, vaccines for protection from Apicomplexan diseases and diagnostic tests for determination active infection with Apicomplexan parasites.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: August 24, 2004
    Inventor: Siobhan P. Ellison
  • Patent number: 6656479
    Abstract: The present invention provides attenuated live cultures of the pathogenic protozoan parasite, Neospora, and live vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: December 2, 2003
    Assignee: Pfizer Inc.
    Inventors: David A Brake, Byron L Blagburn, David S Lindsay
  • Patent number: 6623739
    Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent inducers of a range of immune responses.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: September 23, 2003
    Assignee: SmithKline Beecham Biologicals s.a.
    Inventors: Patricia Marie Momin, Nathalie Marie-Josephe Garcon
  • Publication number: 20030138454
    Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition. There is also provided a method of inducing a CD4+ T-cell response against a target antigen, by administering a composition comprising a source of one or more CD4+ T cell epitopes of the target antigen wherein the source of CD4+ epitopes is a non-replicating or replication impaired recombinant poxvirus vector. A method of inducing a combined CD4+ and CD8+ T cell response against a target antigen is also described herein.
    Type: Application
    Filed: February 19, 2002
    Publication date: July 24, 2003
    Applicant: Oxxon Pharmaccines, Ltd.
    Inventors: Adrian V. S. Hill, Helen McShane, Sarah C. Gilbert, William Reece, Joerg Schneider
  • Patent number: 6436410
    Abstract: The present invention provides isolated polynucleotide molecules comprising a nucleotide sequence encoding the DHFR-TS protein of Neospora which polynucleotide molecules are useful in preparing modified live vaccines against neosporosis, and as diagnostic reagents. The present invention further provides cloning and expression vectors, transformed host cells, substantially purified DHFR-TS proteins and peptide fragments, genetic constructs useful for targeted gene deletion, and vaccine compositions.
    Type: Grant
    Filed: December 2, 1998
    Date of Patent: August 20, 2002
    Assignee: Pfizer, Inc.
    Inventors: B. Rajendra Krishnan, S. Christine Yoder, Becky A. Durtschi
  • Patent number: 6420540
    Abstract: The present invention relates to peptides immunoreactive with antibodies to Toxoplasma gondii, nucleic acid sequences encoding these peptides, recombinant vector molecules, comprising these nucleic acid sequences, host cells transformed with the recombinant vector molecule, immunochemical reagents comprising the peptides or antibodies directed against the peptides, a test kit for the detection of T. gondii infections as well as a vaccine for the protection against T. gondii infections. In particular the present invention provides peptides comprising part of the amino acid sequence as shown in SEQ ID No.: 1. preferred embodiment of the present invention are peptides comprising at least part of the amino acid sequence shown in SEQ ID No.: 3 or 5. It has been found that the peptides according to the present invention are particularly suitable for diagnosing T. gondii infected humans.
    Type: Grant
    Filed: November 4, 1998
    Date of Patent: July 16, 2002
    Assignee: Akzo Nobel N.V.
    Inventors: Marcus Josephus Marie Koolen, Johannes Jozef Wilhelmus De Haard
  • Patent number: 6399077
    Abstract: A method of augmenting T cell-mediated immunity against Toxoplasma gondii is provided. Immunization with Toxoplasma gondii soluble parasite antigen and exogenous rIL-15 was found to protect against Toxoplasma gondii infection.
    Type: Grant
    Filed: May 19, 1999
    Date of Patent: June 4, 2002
    Assignee: Trustees of Dartmouth College
    Inventors: Lloyd H. Kasper, Imtiaz A. Khan
  • Patent number: 6392014
    Abstract: The invention relates to cloning of the gene for the toxoplasma GP28.5 antigen. It also encompasses purified GP28.5 antigen preparations and antigenic polypeptides derived from said antigen, and their applications.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: May 21, 2002
    Inventors: Marie-France Cesbron, Corinne Mercier, André Capron, André Tartar, Pierrette Maes